HMS

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Warnings
Precautions

WARNINGS

Acute purulent infections of the eye may be masked, enhanced or activated by the presence of corticosteroid medication.

Corneal or scleral perforation occasionally has been reported with prolonged use of topical corticosteroids. In high dosages, they have been associated with corneal thinning.

Prolonged use of topical corticosteroids may increase intraocular pressure, with resultant glaucoma, damage to the optic nerve, and defects in visual acuity and fields of vision. However, data from 2 uncontrolled studies 1-2 indicate  that  in  patients  with  increased intraocular pressure and in those susceptible to a rise in intraocular pressure upon application of topical corticosteroids, there is less effect on pressure with HMS® (medrysone 1% liquifilm opthalmic) than with dexamethasone or betamethasone.

Prolonged use of topical corticosteroids may rarely be associated with development of posterior subcapsular cataracts.

Systemic absorption and systemic side effects may result with the use of topical corticosteroids.

HMS® (medrysone 1% liquifilm opthalmic) is not recommended for use in iritis and uveitis as its therapeutic effectiveness has not been demonstrated in these conditions.

Corticosteroid medication in the presence of stromal herpes simplex requires great caution; frequent slit-lamp microscopy is suggested.

Prolonged use may aid in the establishment of secondary ocular infections from fungi and viruses liberated from ocular tissue.

PRECAUTIONS

General:   With prolonged use of HMS® (medrysone 1% liquifilm opthalmic) , the intraocular pressure and the lens should be examined periodically. In persistent corneal ulceration where a corticosteroid has been used, or is in use, fungal infection should be suspected.

Carcinogenesis, mutagenesis, impairment of fertility:   No studies have been conducted in animals or in humans to evaluate the potential of these effects.

Pregnancy Category C:   Medrysone has been shown to be embryocidal in rabbits when given in doses 10 and 30 times the human dose. Medrysone was ocularly applied to both eyes of pregnant rabbits 2 drops 4 times per day on day 6 through 18 of gestation. A significant increase in early resorptions was observed in the treated rabbits. There are no adequate or well-controlled studies in pregnant women. Medrysone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:   Safety and effectiveness in pediatric patients have not been established.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Warnings
Precautions
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.